Kymera and Sanofi move ahead with skin drug af­ter promis­ing PhI da­ta

Kymera and Sanofi plan to move ahead with the skin drug that the French drug­mak­er paid $150 mil­lion in cash in 2020 to part­ner on, af­ter pos­i­tive Phase I re­sults on the IRAK4 de­grad­er they’ve been work­ing on for a pair of skin con­di­tions.

Part C of the ear­ly-stage tri­al ex­am­ined 21 pa­tients with ei­ther hidradeni­tis sup­pu­ra­ti­va or atopic der­mati­tis, with the goal of con­firm­ing the safe­ty da­ta and col­lect­ing da­ta on the change in cir­cu­lat­ing in­flam­ma­to­ry bio­mark­ers and proin­flam­ma­to­ry gene tran­scripts on the skin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER